WHO Removes Remdesivir from Official COVID-19 Treatment List


As the world struggles to beat the COVID-19 pandemic, countless drugs / methods to treat a patient with the endemic disease have been tried to obtain reliable treatment for the disease. This is because the coronavirus is new in all its aspects and a kind of trial and error method is used by doctors and scientists all over the world to strike the heart.

Constant research is being done to know the effectiveness of different drugs and treatment methods, and if they make no difference, the drug ceases to be used as a reliable treatment option.

On a similar note, the Indian Council for Medical Research (ICMR) announced on Monday that research showed convalescent plasma therapy, which was widely used across the country to help patients with COVID-19 recover. restore, was actually of no use. because that doesn’t make much of a difference when it comes to quick recovery or reducing severity. And now, the World Health Organization (WHO) has removed the drug Remdesivir from its list of treatments for COVID-19.

According to the WHO statement, the drug has been suspended from its official medical list. WHO spokesperson Tarik Jasarevik told agencies this suspension is a signal to countries that the WHO, according to treatment guidelines, is not recommending countries to buy the COVID-19 drug , regardless of the degree of illness of a patient as there is no evidence to show that the drug works. India, on the other hand, is experiencing unprecedented demand for drugs and buying them heavily. Its production in the country had also been ramped up and the government had also waived tariffs on its imports while imposing an export ban, following growing demand for the anti-viral.

Also earlier, the WHO found that the drug had no impact on patients infected with the coronavirus and said there was no colossal evidence pointing to medical help being provided by Remdesivir. Due to a lack of evidence, the WHO has recommended countries not to use the drug as a treatment for COVID-19.

On the other hand, Gilead Sciences, the maker of the drug had claimed that the drug was effective against the virus in the United States and said its use was associated with improved clinical recovery and a 62% reduction in risk. mortality compared to standard care. Nevertheless, the WHO expert group found no impact of Remdesivir on mortality.

In Gilead’s opinion, the WHO guidelines seem to “ignore the evidence” from many randomized, controlled studies that indicate the clinical benefits of Remdesivir, such as significantly faster recovery.

When plasma therapy was discontinued as a cure for COVID-19 earlier this week, Dr DS Rana, president of Ganga Ram Hospital said Remdesivir was considered to be withdrawn from the “ line of treatment. even though it has become one of the most crucial weapons in the fight against the coronavirus; only because there is no reliable evidence of its effectiveness and positive impact on a patient.

Remdesivir is a patented drug which is manufactured in India on a large scale under voluntary licenses granted by patent holder Gilead Life Sciences US to seven Indian pharmaceutical companies – Cipla, Dr. Reddy’s, Hetero, Jubilant Pharma, Zydus Cadila, Mylan and Syngene.

Despite the new WHO guidelines, many infectious disease experts believe that remdesivir is the best option we have right now and some even suggest that it may even be part of a cocktail of drugs needed to effectively treat COVID. -19.

Such confusion has been growing ever since the world first saw the novel coronavirus knocking on its doors. The crux of the matter is that no one, not even medical professionals and scientists, knows everything that can be used to fight the virus, to what extent and in what way.

Drugs like ivermectin, hydroxychloroquine, lopiravir / ritonavir, plasma therapy, and drugs like azithromycin and doxycycline have all been excluded from COVID-19 treatments. Further scientific research can further elucidate the complexities. After all, there is still a lot to know about the virus, from its origins to treatment.

Sonakshi Datta

Intern, Goa Chronicle

DISCLAIMER: This article reflects the views of the author. Goa Chronicle may or may not subscribe to the author’s opinions


About Margie Peters

Check Also

My day: Grainne Hughes, Almac Pharma Services

At 8am, I’m in my car and already halfway from the office to Almac’s headquarters …

Leave a Reply

Your email address will not be published.